Price curb likely on Novartis Glivec
National Pharmaceutical Pricing Authority (NPPA) has proposed to impose price control on Swiss pharma giant Novartis' anti-cancer drug Glivec for which the MNC holds a controversial exclusive
National Pharmaceutical Pricing Authority (NPPA) has proposed to impose price control on Swiss pharma giant Novartis' anti-cancer drug Glivec for which the MNC holds a controversial exclusive